Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02684838 · ClinicalTrials.gov registry record

Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry

A clinical trial, sponsored by Arbor Pharmaceuticals.

Completed
Registry status
272
Enrollment target

NCT02684838: Completed study, sponsored by Arbor Pharmaceuticals.

NCT02684838 is a clinical trial that has completed, run by Arbor Pharmaceuticals. The registered enrollment target is 272 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02684838 has completed, sponsored by Arbor Pharmaceuticals.

COMPLETED
Registry status
272 participants
Enrollment target

Study Summary

This is a prospective, observational registry in patients who have been prescribed Gliadel Wafer by the physician as part of usual care.

Primary Outcome

Time from Gliadel placement to death

Trial Details

FieldValue
Enrollment Target 272 participants
Start Date 2016-04-26
Est. Completion 2025-06-23
Arbor Pharmaceuticals

14 total trials

What the finished NCT02684838 record still lists

NCT02684838 is an observational study that tracks outcomes without assigning an intervention. The registered 272 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT02684838 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02684838 about?

NCT02684838 is a clinical study titled "Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry". This is a prospective, observational registry in patients who have been prescribed Gliadel Wafer by the physician as part of usual care.

What is the current status of trial NCT02684838?

This trial is currently completed. The enrollment target is 272 participants. The study started on 2016-04-26. Estimated completion is 2025-06-23.

Who is sponsoring clinical trial NCT02684838?

This trial is sponsored by Arbor Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02468024 · 272 participants · Phase 3

    JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

  • NCT05519449 · 272 participants · Phase 1

    Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  • NCT06035939 · 272 participants · NA

    SMYLS Multi-site Trial

  • NCT06083051 · 272 participants · NA

    Differences in Postoperative Symptoms With Four Ureteral Stents

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02684838, the US trial registry maintained by the National Library of Medicine. NCT02684838 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.